阿立哌唑与利培酮治疗首发精神分裂症对照研究

目的:比较阿立哌唑与利培酮对首发精神分裂症的疗效及安全性.方法:将72例首发精神分裂症住院患者随机分为两组,分别用阿立哌唑和利培酮治疗8周.采用阳性与阴性症状量表(PANSS)评定疗效,用症状量表(TESS)评定药物治疗中的不良反应.结果:两组疗效相仿(P>0.05),阿立哌唑不良反应显著少于利培酮(P<0.05).结论:阿立哌唑治疗首发精神分裂症疗效好,不良反应少.     

阿立哌唑与利培酮治疗老年期精神分裂症对照研究

目的 探讨阿立哌唑治疗精神分裂症的疗效和安全性,并与利培酮对照。方法将66例老年期精神分裂症住院患者随机分为两组,分别用阿立哌唑和利培酮治疗6周。采用阳性与阴性症状量表（PANSS）评定疗效,用治疗中出现的症状量表（TESS）评定不良反应。结果阿立哌唑与利培酮治疗老年期精神分裂症患者的临床疗效差异无统计学意义。两组不良反应少。结论阿立哌唑治疗老年期精神分裂症疗效好、起效快、不良反应少。     

阿立哌唑对女性精神分裂症患者生活质量的影响

目的：探讨阿立哌唑与利培酮对女性精神分裂症患者生活质量的影响。方法：对60例女性精神分裂症患者随机分为两组，分别给予阿立哌唑、利培酮治疗6个月。用阳性症状与阴性症状量表（PANSS）评定精神症状，副反应量表（TESS）评定不良反应，生活质量综合评定问卷（GQOLI）评定生活质量。结果：治疗6个月后阿立哌唑对精神分裂症阳性症状与阴性症状的改善与利培酮相似，两组间PANSS评分差异无显著性（P〉0．05）。阿立哌唑组不良反应在锥体外系（EPS）、体重增加、月经失调等少于利培酮组，两组差异有显著性（P〈0．01）。阿立哌唑组GQOLI总分、躯体健康维度、心理健康维度、社会功能维度较利培酮组有显著改善（P〈0．01）。结论：阿立哌唑组患者生活质量优于利培酮组。     

阿立哌唑与利培酮对精神分裂症患者的疗效及生活质量的影响

目的：比较阿立哌唑与利培酮对精神分裂症患者的疗效及生活质量的影响。方法：将60例精神分裂症患者,随机分为阿立哌唑组（30例）及利培酮组（30例）治疗,疗程8周。分别于治疗前、治疗后2、4、6、8周末,应用阳性与阴性症状量表（PANSS）评定疗效,用副反应量表（TESS）评定治疗过程中出现的不良反应,在治疗前和8周末采用世界卫生组织评定生活质量量表（WHQOL-100）评定生活质量。结果：阿立哌唑对精神分裂症阳性与阴性症状的改善与利培酮相似,均能改善患者的生活质量,阿立哌唑组对生活质量各领域除精神支柱因子外均明显改善,阿立哌唑组除社会关系因子分外其余各因子分均显著高于利培酮组。结论：阿立哌唑更能改善患者的生活质量。     

阿立哌唑与利培酮治疗女性精神分裂症对照研究

目的：比较阿立哌唑与利培酮治疗女性精神分裂症的疗效与安全性。方法：将女性精神分裂症患者40例随机分为阿立哌唑组与利培酮组,治疗8周。采用阳性与阴性症状量表（PANSS）及治疗中出现的症状量表（TESS）评定疗效及不良反应。结果：两组治疗后PANSS评分显著下降,两组间比较差异无显著性（P〉0．05）。阿立哌唑组不良反应显著少于利培酮组（P〈0．05）。结论：阿立哌唑治疗女性精神分裂症疗效与利培酮相仿,不良反应少。     

阿立哌唑与利培酮治疗女性精神分裂症对照研究

目的：探讨阿立哌唑对女性精神分裂症的疗效及安全性。方法：将100例女性精神分裂症患者随机分为阿立哌唑组与利培酮组，每组各50例，阿立哌唑剂量15～30mg/d，利培酮为4～6mg／d；治疗时间8周；采用阳性症状和阴性症状量表（PANss）评定疗效，不良反应量表（TESS）评定不良反应。结果：阿立哌唑组有效率88．0％，利培酮组有效率90．0％，两组疗效比较差异无统计学意义；阿立哌唑组不良反应少于利培酮组。结论：阿立哌唑治疗女性精神分裂症的疗效与利培酮相当，不良反应轻，且对内分泌和体质量影响小。     

阿立哌唑与利培酮治疗精神分裂症对照研究

目的:探讨阿立哌唑治疗精神分裂症的疗效及不良反应.方法:以阿立哌唑与利培酮治疗精神分裂症各30例作为对照研究,疗程8周,采用阳性症状与阴性症状量表(PANSS)、不良反应症状量表(TESS)评定疗效及不良反应.结果:阿立哌唑组显效率76.6%,利培酮组显效率80.3%,两组疗效无显著差异(P>0.05),利培酮组不良反应比阿立哌唑组多.结论:阿立哌唑疗效与利培酮相当,不良反应少,是一种有效、安全的抗精神病药.     

阿立哌唑对精神分裂症患者生活质量的影响

目的：比较阿立哌唑与利培酮对精神分裂症患者生活质量的影响。方法：60例精神分裂症患者随机平分为两组，分别给予阿立哌唑和利培酮治疗。疗程8周。用生活质量综合评定问卷-74（QGOULI-74）、阳性与阴性症状量表（TESS）评定疗效及不良反应。结果：阿立哌唑与利培酮均能显著提高精神分裂症患者生活质量，但阿立哌唑改善QGOULI-74总分、躯体健康及社会功能维度优于利培酮。结论：阿立哌唑有利于提高精神分裂症患者生活质量。     

阿立哌唑对女性精神分裂症患者生活质量的影响

目的探讨阿立哌唑与利培酮对女性精神分裂症患者生活质量的影响.方法对60例女性精神分裂症患者随机分为两组,分别给予阿立哌唑、利培酮治疗6个月.用阳性症状与阴性症状量表(PANSS)评定精神症状,副反应量表(TESS)评定不良反应,生活质量综合评定问卷(GQOLI)评定生活质量.结果治疗6个月后阿立哌唑对精神分裂症阳性症状与阴性症状的改善与利培酮相似,两组间PANSS评分差异无显著性(P＞0.05).阿立哌唑组不良反应在锥体外系(EPS)、体重增加、月经失调等少于利培酮组,两组差异有显著性(P＜0.01).阿立哌唑组GQOLI总分、躯体健康维度、心理健康维度、社会功能维度较利培酮组有显著改善(P＜0.01).结论阿立哌唑组患者生活质量优于利培酮组.     

阿立哌唑与利培酮治疗精神分裂症对照研究

目的：探讨阿立哌唑与利培酮治疗精神分裂症的疗效及不良反应。方法：将符合中国精神障碍分类与诊断标准第3版诊断标准的精神分裂症患者,随机分为阿立哌唑组与利培酮组。疗程8周,采用阳性与阴性症状量表（PANSS）及副反应量表（TESS）评定疗效和不良反应。结果：阿立哌唑组显效率及有效率分别为72%和92%,利培酮组分别为70%和90%,两组疗效相仿（P〉0.05）。阿立哌唑组在治疗2周末阴性症状因子即有明显下降,而利培酮组在治疗4周末才显著下降。阿立哌唑组在锥体外系反应,体质量（体重）增加,失眠等少于利培酮。结论：阿立哌唑对精神分裂症的疗效与利培酮相仿,不良反应轻微,阴性症状改善较快。     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

BLOOD PRESSURE CHANGE WITH AGE IN SALT-SENSITIVE TEENAGERS

Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P＜ 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P＜ 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Dynamic Changes in Serum Estradiol and Progesterone levels in Patients of Premenstrual Syndrome with Adverse Flow of Liver-qi

Objective:To probe into the influence of changes of ovarian hormones on the pathogenesis of the specific sub-type premenstrual syndrome(PMS)and reveal partial microcosmic mechanisms of adverse flow of liver-qi.Methods:Estradiol(E2)and progesterone(P)levels in serum were determined at different phases of menstrual cycle by radioimmunoassay.Results:In the group of PMS with adverse flow of liver-qi.the secretive peak value Of E2 and P at the follicular phase significantly decreased,and the secretive peak value at the luteal phase did not come into being.Conclusions:Low E2 and P secretive peak at the follicular phase and absence of secretive peak at the luteal phase is one of the microcosmic mechanisms of PMS with adverse flow of liver-qi.One of the pathophysiologic mechanisms of specific sub-type PMS is probably the continuous low level of E2and P.     

Real-time Three-dimensional Echocardiography in Assessment of Left Ventricular and Right Ventricular Volumes

Real-time three-dimensional echocardiography (RT3DE)is a new ultrasound technique that enables dynamic threedimensional visualization and quantification of the heart in real time. Investigation of feasibility and methodology of RT3DE in determining left ventricular (LV) and right ventricular (RV) volumes, RT3DE was performed in 35 normal adults using Philips SONOS 7500 system with a 2-4 MHz matrix array transducer. The 60°×60° "pyramid" volume database was obtained and analyzed on a TomTec echo workstation. Both LV and RV volumes were calculated with four 3DE methods (i.e. apical 2, 4, 8, and 16-plane) through manually tracing ventricular endocardial borders in end diastole and end systole. Stroke volumes were then calculated. LV volume was also measured by 2DE Simpson's rule using GE VIVID 7 ultrasound machine.     

SCREENING FOR A 21-CHROMOSOME ABNORMALITY IN PREIMPLANTED EMBRYOS OF ELDERLY WOMEN

Increasing maternal age is the only etiological factor unequivocally linked to Down's syndrome in humans. The occurrence rate of newborns with Down's syndrome is about 1/220 in women over 35 years old. However, the occurrence rate in embryos fertilized in vitro, of the elder woman is unclear. Using FISH we screened the number of chromosome 21 in preimplanted embryos of 5 elderly women (average age, 38.4 years) to study the feasibility and necessity of screening trisomy 21 in embryos in patients over 35 years old at the in vitro fertilization (IVF) center.     

Scientific principles and rigorous processes should be followed in developing clinical guidelines for therapeutic interventions of integrative medicine

A clinical guideline for the therapeutic interventions of integrative medicine may be defined as a written document which states a series of recommendations on therapeutic interventions of integrative medicine for a special disease or condition. The guideline may provide assistance to medical professionals in making clinical decisions aimed at improving the clinical outcome of patients and reducing the costs of medical care（~＇4~. Recommendations issued by a guideline should be based on the best available evidence in both Western and Chinese medicine. For fulfilling this purpose, the development of clinical guidelines for therapeutic interventions in the field of integrative medicine should follow scientific principles and undergo a rigorous processes.